These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10956317)

  • 1. Diabetic nephropathy: evidence for renoprotection and practice.
    Mogensen CE
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i26-8:discussion i50. PubMed ID: 10956317
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K; Christensen PK; Jensen BR; Parving HH
    Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS blockade: new possibilities in the treatment of complications of diabetes.
    Ruilope L
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i32-4:discussion i50. PubMed ID: 10956319
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of beta-blockade and angiotensin converting enzyme inhibition on kidney function in diabetic nephropathy.
    Hommel E
    J Hypertens Suppl; 1989 Sep; 7(7):S49-51. PubMed ID: 2575661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protective effect of antihypertensive agents on renal insufficiency (REIN, RENAAL, IDNT, AASK, etc)].
    Tsuchida H; Kimura K
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():617-22. PubMed ID: 15171445
    [No Abstract]   [Full Text] [Related]  

  • 7. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract]   [Full Text] [Related]  

  • 9. [Kidney and hypertension--evidence based medicine].
    Nakao N; Senou H; Kasuga H; Toriyama T; Kawahara H
    Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1639-45. PubMed ID: 15384696
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antihypertensive treatment in the type 2 diabetic].
    Fournier A
    Nephrologie; 2000; 21(4):203-4. PubMed ID: 10976435
    [No Abstract]   [Full Text] [Related]  

  • 13. Outcome studies in diabetic nephropathy.
    Mohanram A; Toto RD
    Semin Nephrol; 2003 May; 23(3):255-71. PubMed ID: 12838494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different blood-pressure-lowering regimens on major cardiac events.
    Steffen HM; Toex U; Kolloch R
    Lancet; 2004 Jan; 363(9405):331; author reply 331-2. PubMed ID: 14751718
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
    McMurray JJ
    Heart; 2001 Jul; 86(1):97-103. PubMed ID: 11410575
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

  • 20. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
    Nitschmann S; Girndt M; Köhler H
    Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.